QUALITY OF LIFE (QL) ASSESSMENT IS PREDICTIVE OF SURVIVAL IN PATIENTS (PTS) WITH AIDS-RELATED MALIGNANCIES (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

QUALITY OF LIFE (QL) ASSESSMENT IS PREDICTIVE OF SURVIVAL IN PATIENTS (PTS) WITH AIDS-RELATED MALIGNANCIES (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A1424 1992. Unique Identifier : AIDSLINE ICDB/92682153
Remick S; Blanchard C; Portuese E; Wighten T; Powell D; Hilstro J; McSharry J; Haase R; Albany Medical Coll., Albany, NY 12208

Abstract: A total of 43 pts (25 KS + 18 NHL), enrolled in 2 chemotherapy protocols, completed 2 QL scales: Functional Living Index Cancer (FLIC) and Brief Symptom Inventory (BSI) at time of on-study. Clinical variables recorded for each pt included age, sex, performance status (PS), tumor stage, B-symptoms (BS), prior opportunistic infections (POI), CD4 count, survival (OS), FLIC and BSI scores (BSI scales include General Severity Index [GSI], Positive Symptom Distress Index [PSDI], and Positive Symptom Total [PST]). Data were analyzed by discriminant and correlational analyses, proportional hazard models, and product-limit survival analysis. Stepwise discriminant analysis indicated that NHL and KS groups are uniquely discriminated (p less than 0.05) by GSI, BS, OS, POI, and FLIC. Bivariate group differences were also found for PSDI and PST. Product-limit analysis revealed that NHL and KS survival did not differ (p greater than 0.50). Proportional hazard models fitted separately to NHL and KS groups revealed that PSDI, GSI, PST, FLIC, PS, and POI were significantly predictive of survival times (p less than 0.05) for NHL. For the KS group, GSI (p less than 0.01) alone predicted survival. For pooled NHL+KS pts, only PS predicted survival times (p less than 0.01).

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/PHYSIOPATHOLOGY/ PSYCHOLOGY Analysis of Variance Biometry Discriminant Analysis Female Human Lymphoma, Non-Hodgkin's/*COMPLICATIONS/PATHOLOGY/*PHYSIOPATHOLOGY/ PSYCHOLOGY Male Neoplasm Staging Prognosis Proportional Hazards Models *Quality of Life Sarcoma, Kaposi's/*COMPLICATIONS/PATHOLOGY/*PHYSIOPATHOLOGY/ PSYCHOLOGY ABSTRACT
921230
M92C5374

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .